Delanzomib [CEP-18770]

AdipoGen Life Sciences
Product Code: AG-CR1-3673

CodeSizePrice
AG-CR1-3673-M0011 mg£40.00
Quantity:
AG-CR1-3673-M0055 mg£125.00
Quantity:
AG-CR1-3673-M02525 mg£470.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
NPH 007098; CT 47098; CIP 18770; [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
Appearance:
White solid.
CAS:
847499-27-8
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H2,1-3H3,(H,24,28)(H,25,27)/t14-,18+,19+/m1/s1
InChiKey:
SJFBTAPEPRWNKH-CCKFTAQKSA-N
Long Description:
Chemical. CAS: 847499-27-8. Formula: C21H28BN3O5. MW: 413.3. Synthetic. Potent, selective, reversible orally bioavailable proteasome inhibitor. Synthetic P2 threonine boronic acid. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.8nM). Cross-reacts and inhibits the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) beta1 subunit (IC50=~70nM). Displays similar potency for the chymotrypsin-like activity of the proteasome compared to bortezomib. Exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors and bone marrow-derived stromal cells relative to bortezomib. Anticancer compound effective against multiple myeloma in vivo. In vitro, blocks the growth of representative human solid and hematological tumor cell lines (IC50s=5.6-34nM). Shown to down-modulate NF-kappaB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.
MDL:
MFCD18251439
Molecular Formula:
C21H28BN3O5
Molecular Weight:
413.3
Other data:
Note: Warming and sonication may be required when dissolving the compound in the solvent of choice. Stock solutions are stable for at least 1 month when stored at -20°C.
Package Type:
Plastic Vial
Precautions:
P280, P302, P352, P304, P340, P305, P351, P338, P332, P337, P313, P405
Product Description:
Potent, selective, reversible orally bioavailable proteasome inhibitor. Synthetic P2 threonine boronic acid. Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.8nM). Cross-reacts and inhibits the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) beta1 subunit (IC50=~70nM). Displays similar potency for the chymotrypsin-like activity of the proteasome compared to bortezomib. Exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors and bone marrow-derived stromal cells relative to bortezomib (Prod. No. AG-CR1-3602). Anticancer compound effective against multiple myeloma in vivo. In vitro, blocks the growth of representative human solid and hematological tumor cell lines (IC50s=5.6-34nM). Shown to down-modulate NF-kappaB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.
Purity:
>95% (1H-NMR)
Signal word:
Warning
SMILES:
CC(C)C[C@@H](B(O)O)NC([C@H]([C@H](O)C)NC(C1=NC(C2=CC=CC=C2)=CC=C1)=O)=O
Solubility Chemicals:
Soluble in DMSO (20mg/ml) or ethanol (20mg/ml). Slightly soluble in chloroform or methanol. Poorly soluble in water (<1mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer: B.D. Dorsey, et al.; J. Med. Chem. 51, 1068 (2008) | CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib: R. Piva, et al.; Blood 111, 2765 (2008) | The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan: E. Sanchez, et al.; Br. J. Haematol. 148, 569 (2010) | Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE: M.M. Seavey, et al.; Int. Immunopharmacol. 12, 257 (2012) | Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib: C.R. Berkers, et al.; Mol. Pharm. 9, 1126 (2012) | Molecular mechanisms of acquired proteasome inhibitor resistance: A.J. Kale & B.S. Moore; J. Med. Chem. 55, 10317 (2012) | A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma: E. Gallerani, et al.; Eur. J. Cancer 49, 290 (2013) | Proteasome inhibitors in the treatment of multiple myeloma: A. McBride & P.Y. Ryan; Expert Rev. Anticancer Ther. 13, 339 (2013) (Review) | Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma: D.T. Vogl, et al.; Leuk. Lymphoma 58, 1872 (2017)

Related Products

Product NameProduct CodeSupplier 
Carfilzomib [PR-171]AG-CR1-3669AdipoGen Life Sciences Summary Details
Ixazomib [MLN2238]AG-CR1-3670AdipoGen Life Sciences Summary Details
Ixazomib citrate [MLN9708]AG-CR1-3671AdipoGen Life Sciences Summary Details
Oprozomib [ONX 0912]AG-CR1-3672AdipoGen Life Sciences Summary Details
ONX 0914AG-CR1-3674AdipoGen Life Sciences Summary Details
PI-1840 [Proteasome Inhibitor]AG-CR1-3675AdipoGen Life Sciences Summary Details
VR23 [Proteasome Inhibitor]AG-CR1-3676AdipoGen Life Sciences Summary Details